What have we learned about lipids and cardiovascular risk from PCSK9 inhibitor outcomes trials?

Banach, M and Penson, PE (2019) What have we learned about lipids and cardiovascular risk from PCSK9 inhibitor outcomes trials? Cardiovascular Research, 115 (3). pp. 26-31. ISSN 0008-6363

Preview

Text Cardiovascular Research Onlife.pdf - Accepted Version Download (746kB) | Preview

Item Type:	Article
Additional Information:	This is a pre-copyedited, author-produced version of an article accepted for publication in Cardiovascular Research following peer review. The version of record Maciej Banach, Peter E Penson; What have we learned about lipids and cardiovascular risk from PCSK9 inhibitor outcome trials: ODYSSEY and FOURIER?, Cardiovascular Research, Volume 115, Issue 3, 1 March 2019, Pages e26–e31, is available online at: http://dx.doi.org/10.1093/cvr/cvy301
Uncontrolled Keywords:	1102 Cardiorespiratory Medicine and Haematology
Subjects:	R Medicine > RM Therapeutics. Pharmacology
Divisions:	Pharmacy and Biomolecular Sciences
Publisher:	Oxford University Press (OUP)
Related URLs:	https://www.ncbi.nlm.nih.gov/pubmed/30605511
Date of acceptance:	2 December 2018
Date of first compliant Open Access:	3 January 2020
Date Deposited:	26 Feb 2019 09:08
Last Modified:	04 Sep 2021 09:42
DOI or ID number:	10.1093/cvr/cvy301
URI:	https://ljmu-9.eprints-hosting.org/id/eprint/10210

View Item